Journal Article
. 2009 Dec; 58(1):51-6.
doi: 10.1007/s00106-009-2006-0.

[Specific immunotherapy with depigmented allergoids]

L Klimek 1 C Thorn  O Pfaar  
Affiliations
  • PMID: 20011999
  •     23 References
  •     1 citations

Abstract

Specific immunotherapy is the only available causative treatment for IgE-mediated allergic conditions. The state of the art is treatment via the subcutaneous route with crude extracts in a water solution, with physically linked (semidepot) extracts or chemically modified semidepot extracts (allergoids). A relatively new purification method combines depigmentation followed by polymerization with glutaraldehyde. This modification results in increased tolerance with a reduction in both local and systemic adverse effects. As controlled clinical trials have shown, the effectiveness is comparable to that of specific immunotherapy with crude allergen extracts. Recent data suggest that the modified polymerized allergoids allow a safe rush titration in a few days or even in 1 day (ultra-rush titration).

Other Links

Full text on HNO
Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
C Bussmann, L Maintz, +9 authors, N Novak.
Clin Exp Allergy, 2007 Sep 12; 37(9). PMID: 17845407
Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense.
M Casanovas, J Sastre, +3 authors, E Fernández-Caldas.
Clin Exp Allergy, 2005 Oct 22; 35(10). PMID: 16238799
Efficacy and safety of specific immunotherapy with a modified mite extract.
M Branco Ferreira, A Spínola Santos, +3 authors, A G Palma Carlos.
Allergol Immunopathol (Madr), 2005 Apr 06; 33(2). PMID: 15808114
Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.
J Bousquet, R Lockey, H J Malling.
J Allergy Clin Immunol, 1998 Nov 05; 102(4 Pt 1). PMID: 9802362
Highly Cited. Review.
Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up.
D Dokic, J Schnitker, +2 authors, E Frank.
Prilozi, 2006 Jan 10; 26(2). PMID: 16400234
[Allergic rhinoconjunctivitis. Guidelines of the DGAI in association with the DDG].
Claus Bachert, Ulrich Borchard, +6 authors, Johannes Ring.
J Dtsch Dermatol Ges, 2006 Apr 22; 4(3). PMID: 16626325
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.
G B Pajno, G Barberio, +2 authors, S Parmiani.
Clin Exp Allergy, 2001 Oct 10; 31(9). PMID: 11591189
Allergen immunotherapy for asthma.
M J Abramson, R M Puy, J M Weiner.
Cochrane Database Syst Rev, 2003 Oct 30; (4). PMID: 14583928
Systematic Review.
Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus.
M Ibero, M J Castillo.
J Investig Allergol Clin Immunol, 2006 Jun 21; 16(3). PMID: 16784014
Allergen injection immunotherapy for seasonal allergic rhinitis.
M A Calderon, B Alves, +3 authors, S Durham.
Cochrane Database Syst Rev, 2007 Jan 27; (1). PMID: 17253469    Free PMC article.
Highly Cited. Systematic Review.
Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
V A Varney, K Tabbah, G Mavroleon, A J Frew.
Clin Exp Allergy, 2003 Aug 13; 33(8). PMID: 12911781
Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.
José-Carlos García-Robaina, Inmaculada Sánchez, +2 authors, Miguel Casanovas.
J Allergy Clin Immunol, 2006 Nov 08; 118(5). PMID: 17088125
Allergic rhinitis and its impact on asthma.
J Bousquet, P Van Cauwenberge, +2 authors, World Health Organization.
J Allergy Clin Immunol, 2001 Nov 15; 108(5 Suppl). PMID: 11707753
Highly Cited. Review.
Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae.
A Ferrer, J García-Sellés.
J Investig Allergol Clin Immunol, 2004 Mar 03; 13(4). PMID: 14989113
Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life.
E Alvarez-Cuesta, E Aragoneses-Gilsanz, +3 authors, J Cuesta-Herranz.
Clin Exp Allergy, 2005 May 19; 35(5). PMID: 15898977
Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
M Casanovas, R Martín, +2 authors, E Fernández-Caldas.
Int Arch Allergy Immunol, 2005 Dec 24; 139(2). PMID: 16374026
Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
A Ameal, J M Vega-Chicote, +5 authors, J J García-González.
Allergy, 2005 Aug 04; 60(9). PMID: 16076305
Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
Carlos Colás, Susana Monzón, Mónica Venturini, Apolinar Lezaun.
J Allergy Clin Immunol, 2006 Apr 25; 117(4). PMID: 16630938
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation.
A Des Roches, L Paradis, +4 authors, J Bousquet.
Allergy, 1996 Jun 01; 51(6). PMID: 8837669
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).
Christian Möller, Sten Dreborg, +10 authors, Ulrich Wahn.
J Allergy Clin Immunol, 2002 Feb 14; 109(2). PMID: 11842293
Highly Cited.
Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica.
J García-Sellés, A Pascual, +4 authors, J Hernández.
Allergol Immunopathol (Madr), 2003 Mar 21; 31(2). PMID: 12646120
Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts.
M Casanovas, M J Gómez, J Carnés, E Fernández-Caldas.
J Investig Allergol Clin Immunol, 2005 May 04; 15(1). PMID: 15864880
Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment.
F Guerra, J C Daza, E Almeda.
J Investig Allergol Clin Immunol, 2003 Sep 13; 13(2). PMID: 12968395
[Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].
L Klimek, J Willers, +2 authors, G Senti.
HNO, 2013 Oct 16; 61(10). PMID: 24127047